Champions Oncology (CSBR) Q3 2026 earnings review
Core Services Surge, But Strategic Investments Suppress Bottom Line
Champions Oncology's Q3 results represent a tale of two metrics: brilliant top-line core execution masked by heavy investment costs. Total revenue dipped 2.8% YoY to $16.6M, but this was entirely due to a tough comparison against last year's massive $4.5M data license deal. Excluding that data deal, study services revenue skyrocketed 32% YoY. However, this impressive volume recovery did not translate to the bottom line. The company swung to a GAAP operating loss of $276k as operating expenses surged 34% YoY to support data commercialization and over $2M was spent on outsourced radiolabeling work. Adjusted EBITDA remained positive at $574k for the third consecutive quarter, confirming that the business is structurally sound but currently in a heavy investment cycle.
🐂 Bull Case
Excluding the one-time data deal from last year, study service revenue grew 32% YoY. The company is successfully converting delayed backlog into recognized revenue, proving resilient demand for its foundational offerings.
Cost of sales was artificially inflated by over $2M in outsourced radiolabeling work. As management completes the transition to bring this capability in-house, these costs will disappear, creating an immediate tailwind for gross margins.
🐻 Bear Case
Despite record service revenue, total costs and operating expenses skyrocketed 34.3% YoY. R&D and S&M are growing significantly faster than total revenue, pushing the company back into GAAP operating losses.
Operations consumed $1.4M in cash during the quarter due to rising accounts receivable and declining deferred revenue, breaking the positive cash generation narrative established in Q1.
⚖️ Verdict: ⚪
Neutral. The 32% growth in the core study services business is highly encouraging and confirms market share strength. However, the aggressive cash burn and margin compression caused by outsourced work and data investments mean investors must wait a few more quarters to see true operating leverage.
Key Themes
Study Services Conversion (Accelerating)
The foundational study services business is accelerating rapidly. After struggling with cancellations and macro headwinds in FY25, the segment posted record revenue in Q3, up 32% YoY. This acceleration was driven by strong execution and the successful conversion of previously delayed bookings, indicating a stabilization in client R&D spending.
Radiopharmaceutical Services Platform (Innovation)
The launch of the radiopharmaceutical platform is proving highly successful, evidenced by over $2M of work booked in Q3. Currently, this work is outsourced, which drags down margins. However, customer demand is clearly validated, and as Champions brings this capability fully in-house, it will serve as a high-margin growth engine for FY27 and beyond.
Data Platform Investments (Stable)
While Q3 lacked a multi-million dollar data deal like the prior year, management emphasized early momentum in the data business. The company intentionally increased R&D by 32% to advance sequencing activities and increased S&M by 48% to expand the commercial organization, betting heavily that this proprietary data bank will become a cornerstone of future recurring revenue.
Operating Expense Surge Contradicts Profitability Narrative (Decelerating)
Management frequently touts its return to 'profitability' (via Adjusted EBITDA), but the actual data contradicts this positive narrative. Record service revenue failed to generate GAAP operating income. Total costs and operating expenses increased by $4.3M (34.3%), far outpacing total revenue growth. S&M alone surged nearly 48% YoY. Until these investments translate into high-margin data deals, the bottom line will remain suppressed.
Oncology Services Margin Compression (Reversing)
Oncology services margin plummeted to 47%, down sharply from 61% in the prior year and 52% in the immediately preceding quarter (Q2). This reversal was directly caused by the high cost of outsourced lab services for radiolabeling and the lack of high-margin data licensing revenue this quarter. Management execution on bringing this work in-house is now a critical risk factor to monitor.
Negative Operating Cash Flow (Reversing)
After generating positive cash flow in Q1 and maintaining a solid balance sheet, Champions reversed course in Q3, burning $1.4M in cash from operations. This was driven by a buildup in Accounts Receivable (up to $12.1M) and a decline in Deferred Revenue. The cash balance dropped from $9.8M at FY25 year-end to $7.1M.
Biotech Macro Environment Reliance
While management cited 'improving customer engagement' in Q3, the broader biotech funding environment remains a crucial macro overhang. The company's 32% service growth indicates they are winning market share and clearing backlog, but sustained growth requires a broader thawing of early-stage biopharma R&D budgets.
Other KPIs
Stable. This marks the third consecutive quarter of positive Adjusted EBITDA, a significant recovery from the -$1.0M posted in Q4 FY25. However, it represents an 89% deceleration from the $5.1M printed in Q3 FY25 (which included the massive data deal).
Accelerating significantly. Up from $5.9M in Q3 FY25. The 47.6% surge in Sales & Marketing ($2.7M) and 32.1% jump in R&D ($2.3M) show management is aggressively funding its data platform and commercial structure, prioritizing future growth over current GAAP profitability.
Guidance
Accelerating. Management reaffirmed they remain on track to deliver YoY revenue growth for the full fiscal year. With 9-month revenue at $45.6M, they need roughly $11.4M in Q4 to eclipse FY25's $56.9M, which is highly probable given the current $16.6M run rate.
Stable. The company reiterated its expectation for positive adjusted EBITDA for the full year. With $1.5M in Adjusted EBITDA generated over the first nine months, this target is functionally locked in barring a catastrophic Q4.
Key Questions
Radiolabeling In-House Timeline
Outsourced radiolabeling cost you over $2M in margin this quarter. What is the precise operational timeline for bringing 100% of this work in-house, and what steady-state margin can we expect once the transition is complete?
Data Deal Pipeline Visibility
With S&M expenses up 48% to support the commercial data business, when should investors expect the next material (>$1M) data licensing agreement to close?
Working Capital Normalization
Operating cash flow was negative $1.4M driven by AR increases and deferred revenue burn. Is this a temporary timing issue with specific large clients, or a structural change in billing terms to win competitive deals?
Corellia Spin-off Update
You previously noted seeking external VC funding for the Corellia subsidiary to remove its R&D burn from your P&L. Has there been any concrete progress on closing that funding, and how much of Q3's $2.3M R&D expense was dedicated to Corellia?